Trial to evaluate the immunogenicity and safety of a melanoma helper peptide vaccine plus incomplete Freund’s adjuvant, cyclophosphamide, and polyICLC (Mel63) by Kelly T Smith, Nikole Varhegyi, Nolan A Wages, Emily H Hall, Kathleen Haden, Craig L Slingluff, Jr., Lynn T Dengel, Anna Dickinson, Caroline Reed, Elizabeth M Gaughan, Varinder Kaur, Nadejda V Galeassi

Get full text

Phase I/II clinical trial of a helper peptide vaccine plus PD-1 blockade in PD-1 antibody-naïve and PD-1 antibody-experienced patients with melanoma (MEL64) by Ileana S Mauldin, Craig L Slingluff, Gina R Petroni, Walter C Olson, Kimberly A Chianese-bullock, Kelly T Smith, Nikole Varhegyi, William W Grosh, Kathleen Haden, Lynn T Dengel, Elizabeth M Gaughan, Varinder Kaur, Rick Daniel Vavolizza

Get full text

Phase I/II trial of a long peptide vaccine (LPV7) plus toll-like receptor (TLR) agonists with or without incomplete Freund’s adjuvant (IFA) for resected high-risk melanoma by Patrick Hwu, Jason Roszik, Gina R Petroni, Walter C Olson, Kimberly A Chianese-bullock, Kelly T Smith, Nikole Varhegyi, Elizabeth Gaughan, Mark Smolkin, Sacha Gnjatic, Nolan A Wages, Emily H Hall, Kathleen Haden, Sapna P Patel

Get full text

A multipeptide vaccine plus toll-like receptor agonists LPS or polyICLC in combination with incomplete Freund’s adjuvant in melanoma patients by Marit M. Melssen, Gina R. Petroni, Kimberly A. Chianese-Bullock, Nolan A. Wages, William W. Grosh, Nikole Varhegyi, Mark E. Smolkin, Kelly T. Smith, Nadejda V. Galeassi, Donna H. Deacon, Elizabeth M. Gaughan, Craig L. Slingluff

Get full text